<DOC>
	<DOCNO>NCT01047319</DOCNO>
	<brief_summary>To make laquinimod 0.6 mg available subject complete placebo-controlled MS-LAQ-302 study accord protocol evaluate long-term safety , tolerability effect disease course daily oral laquinimod 0.6 mg subject relapse multiple sclerosis .</brief_summary>
	<brief_title>A Study Evaluate Long-term Safety , Tolerability Effect Daily Oral Laquinimod 0.6 mg Disease Course Subjects With Relapsing Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<criteria>1 . Subjects must complete Termination visit MSLAQ302 ( completion Termination visit activity ) accord MSLAQ302 protocol . 2 . Women childbearing potential must practice acceptable method birth control [ acceptable method birth control open label extension phase include : surgical sterilization , intrauterine device , oral contraceptive , contraceptive patch ( hormonereleasing vaginal ring ) , longacting injectable contraceptive , partner 's vasectomy doublebarrier method ( condom diaphragm spermicide ) ] study 30 day last dose study drug.. 3 . Subjects must willing able comply protocol requirement duration study . 4 . Subjects must able comprehend , sign date write informed consent prior enter MSLAQ302E study . 1 . Premature discontinuation MSLAQ302 study , reason . 2 . Pregnancy [ accord urine dipstick Î²HCG test perform Baseline ( Month 0E ) visit ] breastfeeding . 3 . Subjects clinically significant unstable medical surgical condition detect worsened MSLAQ302 study , preclude safe participation completion MSLAQ302E study . Acute exacerbation MS exclude participation MSLAQ302E study . 4 . Use inhibitor CYP3A4 within 2 week prior baseline visit ( V0E , Month 0E ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Relapsing Multiple Sclerosis</keyword>
</DOC>